MCID: DRG002
MIFTS: 40

Drug-Induced Hepatitis malady

Categories: Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Drug-Induced Hepatitis

Aliases & Descriptions for Drug-Induced Hepatitis:

Name: Drug-Induced Hepatitis 38 12 14
Drug-Induced Liver Injury, Chronic 42
Hepatitis, Chronic, Drug-Induced 69
Drug-Induced Chronic Hepatitis 12
Hepatitis, Drug-Induced 69

Classifications:



External Ids:

Disease Ontology 12 DOID:2044
MeSH 42 D056487
SNOMED-CT 64 235889003
UMLS 69 C0524912

Summaries for Drug-Induced Hepatitis

MalaCards based summary : Drug-Induced Hepatitis, also known as drug-induced liver injury, chronic, is related to hepatitis and allopurinol toxicity. An important gene associated with Drug-Induced Hepatitis is NAT2 (N-Acetyltransferase 2), and among its related pathways/superpathways are Metabolism and Cytochrome P450 - arranged by substrate type. The drugs Ursodeoxycholic acid and Cholagogues and Choleretics have been mentioned in the context of this disorder. Affiliated tissues include Liver, liver and testes.

Related Diseases for Drug-Induced Hepatitis

Diseases related to Drug-Induced Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 37)
id Related Disease Score Top Affiliating Genes
1 hepatitis 10.6
2 allopurinol toxicity 10.2 CYP2E1 NAT2
3 differentiated thyroid carcinoma 10.2 GSTM1 GSTT1
4 tuberculosis 10.2
5 lichen planus pigmentosus 10.1 GSTM1 GSTT1
6 cervical adenomyoma 10.1 CYP2E1 GSTM1
7 villous adenoma 10.1 GSTM1 GSTT1
8 gastrointestinal tularemia 10.1 GSTM1 GSTT1
9 tenosynovitis 10.1 GSTM1 GSTT1
10 scrotum squamous cell carcinoma 10.1 CYP2C19 CYP2C9
11 byssinosis 10.1 GSTM1 GSTT1
12 carcinoma of esophagus, salivary gland type 10.1 CYP2C19 CYP2D6
13 anal fistula 10.1 CYP2E1 GSTM1 NAT2
14 mycobacterium kansasii 10.1 GSTM1 GSTT1 NAT2
15 pituitary stalk meningioma 10.1 GSTM1 GSTT1
16 hepatic flexure cancer 10.0 GSTM1 GSTT1 NAT2
17 tinea pedis 10.0 CYP2C19 CYP2D6
18 placenta praevia 10.0 GSTM1 GSTT1 NAT2
19 uvula cancer 10.0 CYP2E1 GSTM1 GSTT1
20 esophageal neuroendocrine tumor 10.0 GSTM1 GSTT1
21 isolated klippel-feil syndrome 10.0 CYP2D6 GSTM1 NAT2
22 cytogenetically normal acute myeloid leukemia 10.0 CYP2C19 CYP2C9
23 pulmonary tuberculosis 10.0
24 retroperitoneal sarcoma 9.9 GSTM1 GSTT1
25 rapsn-related fetal akinesia deformation sequence 9.9 CYP2E1 GSTM1 GSTT1 NAT2
26 maxillary sinusitis 9.9 CYP2C9 CYP2D6 IFNL3
27 hepatitis b 9.7
28 hepatitis a 9.7
29 uremia 9.6 CYP2C19 CYP2C9 CYP2D6 GSTT1 NAT2
30 multiple myeloma 9.6
31 autoimmune hepatitis 9.6
32 melanoma 9.6
33 hyperinsulinism 9.6
34 dystonia 9.6
35 psoriasis 9.6
36 meningitis 9.6
37 emery-dreifuss muscular dystrophy, x-linked 8.8 CYP2C19 CYP2C9 CYP2D6 CYP2E1 GSTM1 GSTT1

Graphical network of the top 20 diseases related to Drug-Induced Hepatitis:



Diseases related to Drug-Induced Hepatitis

Symptoms & Phenotypes for Drug-Induced Hepatitis

Drugs & Therapeutics for Drug-Induced Hepatitis

Drugs for Drug-Induced Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 1,Phase 2 128-13-2 31401
2 Cholagogues and Choleretics Phase 4,Phase 1,Phase 2
3 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
4 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1
5
Ritonavir Approved, Investigational Phase 3 155213-67-5 392622
6
Indinavir Approved Phase 3 150378-17-9 5362440
7
Rifampin Approved Phase 3 13292-46-1 5458213 5381226
8
Efavirenz Approved, Investigational Phase 3 154598-52-4 64139
9
Zidovudine Approved Phase 3 30516-87-1 35370
10
Lamivudine Approved, Investigational Phase 3 134678-17-4 60825
11
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-24-8 5755
12
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 83-43-2 6741
13
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
14
Tenofovir Approved, Investigational Phase 3 147127-20-6 464205
15
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
16 Prednisolone acetate Phase 3,Phase 2,Phase 1
17 glucocorticoids Phase 3,Phase 2,Phase 1
18
protease inhibitors Phase 3
19 N-monoacetylcystine Phase 2, Phase 3
20 Neuroprotective Agents Phase 3,Phase 2,Phase 1
21 HIV Protease Inhibitors Phase 3
22 Cytochrome P-450 CYP2C9 Inhibitors Phase 3
23 Cytochrome P-450 CYP3A Inducers Phase 3
24 Cytochrome P-450 CYP3A Inhibitors Phase 3
25 Cytochrome P-450 Enzyme Inhibitors Phase 3
26 Nucleic Acid Synthesis Inhibitors Phase 3
27 Hormone Antagonists Phase 3,Phase 2,Phase 1
28 Hormones Phase 3,Phase 2,Phase 1
29 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
31 Anti-Bacterial Agents Phase 2, Phase 3
32 Anti-HIV Agents Phase 3
33 Prednisolone hemisuccinate Phase 3,Phase 2,Phase 1
34 Prednisolone phosphate Phase 3,Phase 2,Phase 1
35 Expectorants Phase 2, Phase 3
36 Anti-Infective Agents Phase 3,Phase 2
37 Protective Agents Phase 2, Phase 3, Phase 1
38 Antidotes Phase 2, Phase 3
39 Antiemetics Phase 3,Phase 2,Phase 1
40 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
41 Antimetabolites Phase 3,Phase 2
42 Anti-Retroviral Agents Phase 3
43 Respiratory System Agents Phase 2, Phase 3
44 Antibiotics, Antitubercular Phase 3
45 Reverse Transcriptase Inhibitors Phase 3
46 Methylprednisolone acetate Phase 3,Phase 2,Phase 1
47 Methylprednisolone Hemisuccinate Phase 3,Phase 2,Phase 1
48 Autonomic Agents Phase 3,Phase 2,Phase 1
49 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
50 Antitubercular Agents Phase 2, Phase 3

Interventional clinical trials:

(show all 22)
id Name Status NCT ID Phase
1 Cholestatic Drug-induced Liver Injury Unknown status NCT01141322 Phase 4
2 Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN) Completed NCT00158405 Phase 3
3 A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis Recruiting NCT02182167 Phase 2, Phase 3
4 Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis Recruiting NCT02273765 Phase 3
5 Comparison of Bovine Colostrum Versus Placebo in Treatment of Severe Alcoholic Hepatitis: A Randomized Double Blind Controlled Trial Not yet recruiting NCT02473341 Phase 3
6 Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis Unknown status NCT01661842 Phase 1, Phase 2
7 Efficacy of Combination Therapy of Glucocorticoids and Bovine Colostrum in Treatment of Severe Alcoholic Hepatitis. Completed NCT02265328 Phase 2
8 Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C Completed NCT02226939 Phase 2
9 Efficacy and Safety of Glucocorticosteroid Treatment in the Patients With Chronic Recurrent DILI Recruiting NCT02651350 Phase 1, Phase 2
10 Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure Recruiting NCT01548690 Phase 2
11 Sonoelastography: Ultrasound Method to Measure Liver Fibrosis Unknown status NCT01747772
12 Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases Unknown status NCT01200082
13 Risk of Acute Liver Injury in Users of Antimicrobials Completed NCT01434173
14 Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis Completed NCT00834353
15 Anti-tuberculosis (TB) Drug Levels and Hepatotoxicity Completed NCT00929786
16 Anti-tuberculosis (TB) Drug Levels and Correlation With Drug Induced Hepatotoxicity Completed NCT01456845
17 Investigation of the Effect of N Acetylcysteine Against Anti-Tuberculosis Drugs Induced Liver Toxicity Completed NCT00564642
18 The Efficacy of Silymarin on the Prevention of Hepatotoxicity From Antituberculosis Drugs Completed NCT01800487
19 A Prospective Cohort Study on Drug-induced Liver Injury in China(DILI-P) Recruiting NCT02961413
20 DILIN's Prospective Study Recruiting NCT00345930
21 Study of the Clinical Features of Autoimmune Hepatitis Recruiting NCT02994537
22 Ultrasound Method to Measure Fibrosis of the Liver in Children Terminated NCT02086708

Search NIH Clinical Center for Drug-Induced Hepatitis

Cochrane evidence based reviews: drug-induced liver injury, chronic

Genetic Tests for Drug-Induced Hepatitis

Anatomical Context for Drug-Induced Hepatitis

MalaCards organs/tissues related to Drug-Induced Hepatitis:

39
Liver, Testes, T Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Drug-Induced Hepatitis:
id Tissue Anatomical CompartmentCell Relevance
1 Liver Liver Lobule Hepatocytes Affected by disease

Publications for Drug-Induced Hepatitis

Articles related to Drug-Induced Hepatitis:

(show top 50) (show all 96)
id Title Authors Year
1
Compensatory variances of drug-induced hepatitis B virus YMDD mutations. ( 27588233 )
2016
2
Analysis of IL-6, STAT3 and HSPA1L Gene Polymorphisms in Anti-Tuberculosis Drug-Induced Hepatitis in a Nested Case-Control Study. ( 25789467 )
2015
3
Characteristics of Mononuclear Extracellular Traps in the Offspring of Female Rats with Drug-Induced Hepatitis. ( 26388577 )
2015
4
Troxis necrosis, a novel mechanism for drug-induced hepatitis secondary to immunomodulatory therapy. ( 26297838 )
2015
5
Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients. ( 25949974 )
2015
6
Recurrent Drug-Induced Hepatitis in Tuberculosis-Comparison of Two Drug Regimens. ( 26057141 )
2015
7
Superoxide Dismutase Gene (SOD1, SOD2, and SOD3) Polymorphisms and Antituberculosis Drug-induced Hepatitis. ( 25553268 )
2015
8
Authors' reply to Comment on "No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance" [Dig. Liver Dis.2014;46:348-52]. ( 24890620 )
2014
9
Is antiviral drug-induced hepatitis B surface antigen loss durable? ( 25457852 )
2014
10
Risk factors for drug-induced hepatitis with first-line antituberculosis drugs in hospitalized patients of pulmonary tuberculosis. ( 24823543 )
2014
11
Comment on "No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance" by Ubaldo Visco-Comandini et al. [Dig. Liver Dis. 2014;46:348-52]. ( 24815081 )
2014
12
Comments on 'Risk factors for drug induced hepatitis with first-line antituberculosis drugs in hospitalized patients of pulmonary tuberculosis'. ( 24823542 )
2014
13
Epstein-Barr Virus Infection Mimicking Drug-Induced Hepatitis in a Critically ill Patient During Antituberculosis Therapy. ( 25368656 )
2014
14
Risk factors for drug induced hepatitis with first-line antituberculosis drugs in hospitalized patients of pulmonary tuberculosis. ( 24625953 )
2014
15
Efficacy of herbal coded Hepcon on drug induced hepatitis in experimental animals through histopathological and biochemical analysis. ( 24035958 )
2013
16
A rare coexistence: drug induced hepatitis and meningitis in association with Ibuprofen. ( 23671551 )
2013
17
Hyperacute drug-induced hepatitis with intravenous amiodarone: case report and review of the literature. ( 24109195 )
2013
18
No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance. ( 24387833 )
2013
19
Cytochrome P450 2E1 gene polymorphisms/haplotypes and anti-tuberculosis drug-induced hepatitis in a Chinese cohort. ( 23460870 )
2013
20
A rare cause of drug-induced hepatitis in an immunocompromised patient and the role of glutathione. ( 22993667 )
2012
21
TNF-I+ genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis. ( 22151084 )
2012
22
Anti-tuberculosis drug-induced hepatitis in renal transplant patient with pulmonary and extra pulmonary tuberculosis. ( 23960791 )
2012
23
A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma. ( 22916049 )
2012
24
Drug-induced hepatitis following use of octreotide for long-term treatment of congenital hyperinsulinism. ( 22850563 )
2012
25
A Case of Drug-Induced Hepatitis due to Lenalidomide. ( 21552449 )
2011
26
[Relationship between the polymorphisms of UGT1A6 genes and anti-tuberculosis drug induced hepatic-injury]. ( 21586239 )
2011
27
Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. ( 22012226 )
2011
28
NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. ( 20392357 )
2010
29
Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases. ( 19535968 )
2010
30
Zhixue capsule caused seven cases of drug induced hepatitis. ( 20698229 )
2010
31
Remission of drug-induced hepatitis after switching from risperidone to paliperidone. ( 20194492 )
2010
32
Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review. ( 20338127 )
2010
33
[The effect of GST M1 and GST T1 gene mutations on anti-tuberculous drug induced hepatic injury]. ( 19576039 )
2009
34
Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. ( 19891553 )
2009
35
Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. ( 18830542 )
2008
36
Drug-induced hepatitis superimposed on the presence of anti-SLA antibody: a case report. ( 18226219 )
2008
37
Acute drug-induced hepatitis caused by albendazole. ( 18955802 )
2008
38
Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests. ( 18330759 )
2008
39
Acute drug induced hepatitis secondary to a weight loss product purchased over the internet. ( 17597525 )
2007
40
Drug-induced hepatitis - morphological and ultrastructural aspects. ( 18060200 )
2007
41
Rescue therapy by portal infusion of autologous stem cells in a case of drug-induced hepatitis. ( 16875890 )
2007
42
Drug induced hepatitis with anti-tubercular chemotherapy: challenges and difficulties in treatment. ( 18604033 )
2007
43
Acute drug induced hepatitis due to erlotinib. ( 17228132 )
2007
44
Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfibrozil in therapy. ( 16645237 )
2006
45
A case of acute drug-induced hepatitis. ( 16607204 )
2006
46
Mitochondrial involvement in drug-induced hepatic injury. ( 16889760 )
2006
47
Khat--a novel cause of drug-induced hepatitis. ( 16864024 )
2006
48
Role of CYP2E1 immunoglobulin G4 subclass antibodies and complement in pathogenesis of idiosyncratic drug-induced hepatitis. ( 16467335 )
2006
49
Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. ( 16728538 )
2006
50
Drug-induced hepatitis with saquinavir/ritonavir + rifampin. ( 15828118 )
2005

Variations for Drug-Induced Hepatitis

Expression for Drug-Induced Hepatitis

Search GEO for disease gene expression data for Drug-Induced Hepatitis.

Pathways for Drug-Induced Hepatitis

Pathways related to Drug-Induced Hepatitis according to GeneCards Suite gene sharing:

(show all 28)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 CYP2C19 CYP2C9 CYP2D6 CYP2E1 GSTM1 GSTT1
2
Show member pathways
12.86 CYP2C19 CYP2C9 CYP2D6 CYP2E1 GSTM1 GSTT1
3
Show member pathways
11.81 CYP2C19 CYP2C9 CYP2D6 CYP2E1 GSTM1 GSTT1
4
Show member pathways
11.79 CYP2C19 CYP2C9 CYP2E1
5 11.75 CYP2C19 CYP2C9 CYP2D6
6
Show member pathways
11.64 CYP2C19 CYP2C9 CYP2D6 UGT1A3
7
Show member pathways
11.52 CYP2C19 CYP2C9 CYP2D6
8 11.5 GSTM1 GSTT1
9
Show member pathways
11.45 CYP2D6 CYP2E1 GSTM1 GSTT1 UGT1A3
10
Show member pathways
11.44 CYP2E1 UGT1A3
11
Show member pathways
11.42 CYP2C19 CYP2C9 CYP2D6 CYP2E1
12
Show member pathways
11.36 CYP2C19 CYP2C9
13 11.33 CYP2C19 CYP2C9
14
Show member pathways
11.33 CYP2C19 CYP2C9 CYP2D6
15
Show member pathways
11.26 GSTM1 NAT2
16 11.18 CYP2C19 CYP2D6
17 11.15 CYP2C9 CYP2E1
18 11.14 CYP2C19 CYP2C9 UGT1A3
19
Show member pathways
11.14 CYP2C19 CYP2C9 CYP2D6 CYP2E1 UGT1A3
20
Show member pathways
11.13 GSTM1 UGT1A3
21 11.05 GSTM1 GSTT1
22
Show member pathways
11.04 CYP2C9 CYP2E1 NAT2
23
Show member pathways
11.02 CYP2C9 CYP2E1
24 11 CYP2C9 CYP2E1 GSTM1 GSTT1
25 10.9 CYP2C9 UGT1A3
26 10.87 CYP2C9 CYP2E1
27 10.67 CYP2C9 UGT1A3
28 10.29 CYP2E1 GSTM1

GO Terms for Drug-Induced Hepatitis

Cellular components related to Drug-Induced Hepatitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.65 CYP2C19 CYP2C9 CYP2D6 CYP2E1 UGT1A3
2 endoplasmic reticulum membrane GO:0005789 9.55 CYP2C19 CYP2C9 CYP2D6 CYP2E1 UGT1A3
3 intracellular membrane-bounded organelle GO:0043231 9.35 CYP2C19 CYP2C9 CYP2D6 CYP2E1 UGT1A3
4 organelle membrane GO:0031090 8.92 CYP2C19 CYP2C9 CYP2D6 CYP2E1

Biological processes related to Drug-Induced Hepatitis according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.81 CYP2C19 CYP2C9 CYP2D6 CYP2E1
2 steroid metabolic process GO:0008202 9.67 CYP2C19 CYP2C9 CYP2D6 CYP2E1
3 glutathione metabolic process GO:0006749 9.52 GSTM1 GSTT1
4 epoxygenase P450 pathway GO:0019373 9.5 CYP2C19 CYP2C9 CYP2E1
5 glutathione derivative biosynthetic process GO:1901687 9.49 GSTM1 GSTT1
6 exogenous drug catabolic process GO:0042738 9.48 CYP2C19 CYP2C9
7 oxidative demethylation GO:0070989 9.46 CYP2C9 CYP2D6
8 drug metabolic process GO:0017144 9.46 CYP2C19 CYP2C9 CYP2D6 CYP2E1
9 omega-hydroxylase P450 pathway GO:0097267 9.43 CYP2C19 CYP2C9
10 heterocycle metabolic process GO:0046483 9.43 CYP2C19 CYP2D6 CYP2E1
11 drug catabolic process GO:0042737 9.4 CYP2C9 CYP2D6
12 xenobiotic metabolic process GO:0006805 9.35 CYP2C19 CYP2C9 CYP2D6 CYP2E1 NAT2
13 monoterpenoid metabolic process GO:0016098 8.92 CYP2C19 CYP2C9 CYP2D6 CYP2E1

Molecular functions related to Drug-Induced Hepatitis according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.83 CYP2C19 CYP2C9 CYP2D6 CYP2E1
2 enzyme binding GO:0019899 9.71 CYP2C19 CYP2E1 GSTM1
3 iron ion binding GO:0005506 9.67 CYP2C19 CYP2C9 CYP2D6 CYP2E1
4 heme binding GO:0020037 9.62 CYP2C19 CYP2C9 CYP2D6 CYP2E1
5 drug binding GO:0008144 9.55 CYP2C9 CYP2D6
6 glutathione transferase activity GO:0004364 9.51 GSTM1 GSTT1
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.49 CYP2D6 CYP2E1
8 steroid hydroxylase activity GO:0008395 9.48 CYP2C19 CYP2C9
9 (S)-limonene 7-monooxygenase activity GO:0018676 9.46 CYP2C19 CYP2C9
10 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.46 CYP2C19 CYP2C9 CYP2D6 CYP2E1
11 (S)-limonene 6-monooxygenase activity GO:0018675 9.43 CYP2C19 CYP2C9
12 arachidonic acid epoxygenase activity GO:0008392 9.43 CYP2C19 CYP2C9 CYP2E1
13 (R)-limonene 6-monooxygenase activity GO:0052741 9.4 CYP2C19 CYP2C9
14 monooxygenase activity GO:0004497 9.26 CYP2C19 CYP2C9 CYP2D6 CYP2E1
15 oxygen binding GO:0019825 8.92 CYP2C19 CYP2C9 CYP2D6 CYP2E1

Sources for Drug-Induced Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....